

Effect of BMI on toxicities and survival among adolescents and young adults treated on DFCI Consortium ALL trials

Shai Shimony,^{1,2} Yael Flamand,³ Yannis K. Valtis,⁴ Andrew E. Place,⁵ Lewis B. Silverman,⁵ Lynda M. Vrooman,⁵ Andrew M. Brunner,⁶ Stephen E. Sallan,⁵ Richard M. Stone,¹ Martha Wadleigh,¹ Donna S. Neuberg,³ Daniel J. DeAngelo,¹ and Marlise R. Luskin¹

¹Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; ²Hematology Department, Rabin Medical Center and Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; ³Department of Data Science, Dana-Farber Cancer Institute, Boston, MA; ⁴Department of Medicine, Memorial Sloan Kettering Cancer Institute, New York, NY; ⁵Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, MA; and ⁶Leukemia Department, Hematology/Oncology, Massachusetts General Hospital, Boston, MA

Key Points

- Elevated BMI is associated with increased toxicity and NRM, and decreased OS among AYAs treated on DFCI consortium pediatric ALL regimens.
- Normal BMI is associated with excellent outcomes, regardless of age; the deleterious effect of increased BMI is more pronounced in older AYAs.

Adolescent and young adults (AYAs) with acute lymphoblastic leukemia (ALL) treated with asparaginase-containing pediatric regimens are commonly overweight or obese. We studied the association of body mass index (BMI) on outcomes of 388 AYAs aged 15 to 50 years treated on Dana-Farber Cancer Institute (DFCI) consortium regimens (2008-2021). BMI was normal in 207 (53.3%) and overweight/obese in 181 (46.7%). Patients who were overweight or obese experienced higher nonrelapse mortality (NRM; 4-year, 11.7% vs 2.8%, $P = .006$), worse event-free survival (4-year, 63% vs 77%, $P = .003$), and worse overall survival (OS; 4-year, 64% vs 83%, $P = .0001$). Because younger (aged 15-29 years) AYAs more frequently had a normal BMI (79% vs 20%, $P < .0001$), we conducted separate analyses in each BMI group. We found excellent OS among younger and older (30-50 years) AYAs with normal BMI (4-year OS, 83% vs 85%, $P = .89$). Conversely, in AYAs who were overweight/obese, worse outcomes were seen in older AYAs (4-year OS, 55% vs 73%, $P = .023$). Regarding toxicity, AYAs who were overweight/obese experienced higher rates of grade 3/4 hepatotoxicity and hyperglycemia (60.7% vs 42.2%, $P = .0005$, and 36.4% vs 24.4%, $P = .014$, respectively) but had comparable rates of hypertriglyceridemia (29.5% vs 24.4%, $P = .29$). In a multivariable analysis, higher BMI was associated with worse OS, hypertriglyceridemia was associated with improved OS, and age was not associated with OS. In conclusion, among AYAs treated on DFCI Consortium ALL regimens, elevated BMI was associated with increased toxicity, increased NRM, and decreased OS. The deleterious effect of elevated BMI was more pronounced in older AYAs.

Introduction

Adolescent and young adult (AYA) patients with acute lymphoblastic leukemia (ALL) have favorable outcomes when treated with pediatric ALL regimens.^{1,2} Pediatric regimens are believed to be effective because of intensive use of the nonmyelosuppressive agents asparaginase, corticosteroids, and vincristine, in combination with other chemotherapies. Asparaginase is a uniquely effective drug for the treatment of ALL but is also associated with a distinct set of adverse events including metabolic toxicities (hepatotoxicity, hyperglycemia, and hypertriglyceridemia), hypersensitivity, venous

Submitted 15 February 2023; accepted 16 May 2023; prepublished online on *Blood Advances* First Edition 11 July 2023. <https://doi.org/10.1182/bloodadvances.2023009976>.

The data that support the findings of this study are available on request from the corresponding author, Marlise R. Luskin (marlise_luskin@dfci.harvard.edu). The data are not publicly available due to privacy or ethical restrictions.

The full-text version of this article contains a data supplement.

© 2023 by The American Society of Hematology. Licensed under [Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International \(CC BY-NC-ND 4.0\)](#), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.




Figure 1. ALL DFCI consortium treatment protocols. Including pediatric protocols (00-001 and 05-001) and pediatric-inspired protocols (01-175 and 06-254). Asparaginase administration is marked in red. CNS, central nervous system.

thromboembolism, pancreatitis, and orthopedic complications.³⁻⁵ Although pediatric ALL regimens have been shown to be tolerable in older children, adolescents, and young adults, the regimens are known to incur more toxicity in AYAs compared with in younger children.⁶

Obesity is a serious and worsening noninfectious health pandemic. The rate of obesity, defined as a body mass index (BMI) of $>30 \text{ mg/m}^2$ in adults and in children, a BMI $\geq 95\%$ percentile, is rising among children, adolescents, and adults. The estimated prevalence of obesity among adults rose from 30.5% in 1999 to 2000, to 41.9% in 2017 to 2020 and also affects 19.7% of children.⁷ Importantly, in addition to being associated with liver disease, diabetes, cardiovascular disease, and cancer,⁸⁻¹¹ obesity has been specifically associated with adverse outcomes in children with ALL receiving asparaginase-containing chemotherapy regimens.^{12,13} Especially concerning for patients with ALL is the reported association of obesity with increased risk of death, an association shown in both pediatric and adult cohorts.^{14,15}

Although both age and obesity are reportedly associated with increased risk of treatment-related adverse events and death in patients being treated for ALL, a detailed understanding of the influence of obesity on metabolic toxicities, disease response, and survival in AYAs with ALL treated with pediatric regimens is limited. Thus, we aimed to assess the association between obesity and outcomes among AYA patients aged 15 to 50 years with ALL treated in accordance with Dana-Farber Cancer Institute (DFCI) consortium pediatric ALL regimens, which incorporate 30 weeks of continuous asparaginase depletion during postremission therapy.

Methods

Patients

We included all patients aged 15 to 50 years ($n = 308$) treated on 4 sequential multicenter DFCI ALL Consortium protocols: Pediatric 00-001¹⁶ and Adult 01-175¹⁷ (older protocols); Pediatric 05-001¹⁸ and Adult 06-254¹⁹ (newer protocols). All protocols include an induction phase, a consolidation phase that includes 30 weeks of continuous asparaginase depletion, and a continuation phase that continues until 2 years from achievement of complete

remission (CR, Figure 1). The older protocols used native *Escherichia Coli* asparaginase preparation, whereas the newer protocols incorporated pegylated asparaginase. In addition, we included all consecutive patients ($n = 80$) who were treated per these protocols at DFCI, Boston Children's Hospital, and Massachusetts General Hospital between 2001 and 2021 with data extracted from the electronic medical record. BMI at diagnosis was used as a standardized measure of obesity and was calculated based on Center for Disease Control guidelines, per age-adjusted percentiles for patients aged 2 to 20 years (underweight: BMI $< 5\%$ percentile; normal: BMI within 5%-84.99% percentiles; overweight: BMI within 85%-94.99% percentiles; obese: BMI $\geq 95\%$ percentile) and per absolute BMI (kg/m^2) in patients aged ≥ 20 years (underweight: BMI $< 18.5 \text{ kg/m}^2$; normal: BMI of 18.5-24.99 kg/m^2 ; overweight: BMI of 25-29.99 kg/m^2 ; and obese: BMI of $\geq 30 \text{ kg/m}^2$). For this analysis, underweight and normal categories were unified.

Outcomes

Overall survival (OS) was defined as time from diagnosis to death from any cause, censored at date of last follow-up. Event-free survival (EFS) was defined as time from diagnosis to relapse, second cancer, or death, censored at date of last follow-up. Toxicities were determined by Common Terminology Criteria for Adverse Events 2.0 and 3.0, per the specific trial guidelines or by Common Terminology Criteria for Adverse Events 3.0 for patients treated per protocols. Hepatotoxicity was defined as either elevated alanine aminotransferase (ALT), aspartate aminotransferase (AST), and/or total bilirubin. Toxicity grade was determined both as the highest (per patient) per each treatment phase and highest (per patient) per entire treatment course.

Statistics

Categorical variables are summarized as numbers and percentages, and comparisons were made by Pearson χ^2 or Fisher exact tests, as appropriate. Continuous variables are summarized as median and range, and comparisons were made by Mann-Whitney tests. OS and EFS were estimated by the Kaplan-Meier method, with the log-rank test used to compare survival curves. Cox proportional hazard regression models were fitted to assess the effect

of covariates on survival outcomes in univariate and multivariable models. Covariates, which were found to be significant in a univariate setting at a significance level of $P < .05$, were included in the initial multivariable model. Backward selection was performed, retaining variables with a $P < .05$ in the final model. Allogeneic stem cell transplantation (alloSCT) was included as a time-varying covariate. The cumulative incidence of relapse (CIR) and nonrelapse mortality (NRM) were estimated by the cumulative incidence method, identifying death by any cause or relapse as a competing risk, respectively, and tested using the Gray test. For all analyses, confidence intervals (CI) were calculated at the (2-sided) 95% level of confidence. A 2-sided P value of $< .05$ was considered statistically significant. All statistics were performed with STATA version 17.0, SAS version 9.4, and the “cmprsk” package in R.

This study was conducted with the approval of the institutional review board at the DFCI.

Results

Patients and treatment

Overall, 388 patients were included in our analysis. Most patients were male ($n = 240$, 61.9%) and the median age was 24 years (range, 15-50 years), with 254 (65%) aged 15 to 29 years (younger AYAs) and 134 (35%) aged 30 to 50 years (older AYAs). BMI at diagnosis was underweight ($n = 10$, 2.6%) or normal ($n = 197$, 50.7%) in slightly more than half of patients ($n = 207$, 53.3%, normal BMI group) with the remainder of patients having a BMI of overweight ($n = 97$, 25%) or obese ($n = 84$, 21.7%; combined overweight/obese group, $n = 181$, 46.7%, [Table 1](#)). Patients in the normal BMI vs overweight/obese groups were more likely to be female (44% vs 32%, $P = .02$) and were younger (median age, 20 years [range, 15-50 years] vs 30 years [range, 15-50 years]; $P < .001$). Given that patients in the normal BMI group were younger compared with those in the overweight/obese group, they had lower rates of *BCR::ABL1* translocation (7% vs 19%, $P < .001$) and higher rates of hyperdiploid karyotype (14% vs 6%, $P = .006$). Central nervous system involvement was present in 56 patients (14%) at diagnosis and was not different between normal and overweight/obese BMI groups (14% vs 15%, $P = .7$).

Approximately one-third ($n = 127$, 33%) of patients were treated on earlier *E coli* asparaginase-based DFCI protocols (00-001 and 01-175, [Figure 1](#); supplemental Table 1). The remaining patients ($n = 261$, 67%) were treated on ($n = 181$), or per ($n = 80$) later protocols (05-001 and 06-254), primarily receiving pegylated asparaginase, without any difference between the normal vs overweight/obese BMI groups ($P = .12$).

Toxicities

Comprehensive toxicity data were available for all patients except 35 patients enrolled in the older pediatric 00-001 trial. Thus, the toxicity analysis was based on 353 (91%) patients. During the entire treatment course, the rate of any grade 3/4 hepatotoxicity (elevation of AST, ALT, and/or bilirubin) was higher in patients who were overweight/obese vs those with a normal BMI (60.7% vs 42.2%, $P = .0005$, [Figure 2](#)). The rate of each individual grade 3/4 liver toxicity was also higher in patients who were overweight/obese vs those with a normal BMI (AST: 26.6% vs 14.4%, $P = .005$; ALT: 50.3% vs 38.9%, $P = .031$; and bilirubin: 23.1% vs

6.7%, $P < .0001$, respectively). Likewise, the rate of grade 3/4 hyperglycemia was higher among patients who were overweight/obese vs those with normal BMI (36.4% vs 24.4%, $P = .014$). Conversely, no significant difference in grade 3/4 hypertriglyceridemia was seen in patients who were overweight/obese vs those with a normal BMI (29.5% vs 24.4%, $P = .29$, [Table 2](#)). A direct association between BMI and toxicity rates was also seen when BMI was stratified by 3 groups (normal, overweight, and obese, supplemental Table 2). Of note, the type of asparaginase (pegylated vs nonpegylated) did not affect hepatotoxicity and hyperglycemia toxicity rates, but the rate of grade 3/4 hypertriglyceridemia was higher among patients treated with pegylated vs nonpegylated asparaginase (supplemental Table 3). In addition, being treated on protocol vs as per protocol was associated with lower rates of grade 3/4 toxicities (supplemental Table 4).

When analyzed separately by age group, younger AYAs with overweight/obese vs normal BMI were more likely to experience grade 3/4 hepatotoxicity (58.5% vs 38.0%, $P = .003$). Conversely, in older AYAs, no significant difference in grade 3/4 hepatotoxicity was seen between the different BMI groups (62.6% vs 55.8%, $P = .45$). Similarly, regarding hyperglycemia, in younger AYAs, the rate of grade 3/4 hyperglycemia was higher among patients who were overweight/obese vs those with a normal BMI (36.6% vs 22.6%, $P = .026$) but no significant difference was seen in the older AYAs (36.3% vs 30.2%, $P = .49$). Grade 3/4 hypertriglyceridemia rates did not differ by BMI groups in the entire cohort or when separated by age group ([Figure 2](#)).

Bacterial or fungal infection were reported in 52 patients (13%) and did not differ between patients with a normal BMI vs those with overweight/obese BMI (15% [$n = 32$] vs 11% [$n = 20$], $P = .20$).

The timing of toxicities varied. Grade 3/4 hepatotoxicity was common in all treatment phases: present in 23.6%, 38.5%, and 23.8% of AYAs during induction, consolidation, and continuation, respectively. Grade 3/4 hyperglycemia was most common during induction (23.6%), less common during consolidation (16.5%), and rare during continuation (5.3%). Grade 3/4 hypertriglyceridemia was rare during induction (3.6%) and maintenance (2%), but common during consolidation (29.9%).

Response, survival, and relapse

CR was achieved in 87% of patients, without a difference between normal and overweight/obese BMI groups ($P = .84$). Similarly, induction failure and early death rates (within 30 days) were comparable between patients in the normal vs overweight/obese BMI groups (6% vs 8%, $P = .42$ and 2% in both groups [$P = .4$], respectively). AlloSCT was performed in 70 patients, with 79% (55/70) performed at CR1. Transplant rates at CR1 were comparable between patients with normal (75%, 24/32) vs overweight/obese BMI (82% [31/38], $P = .5$).

With a median follow-up of 5.5 years, the 4-year OS was 74% (95% CI, 69-78), higher in younger vs older AYA patients (79% [95% CI, 73-84] vs 64% [95% CI, 55-72], $P = .003$), and higher in patients with normal vs overweight/obese BMI (83% [95% CI, 77-88] vs 64% [95% CI, 56-71], $P = .0001$). Because of the association between age group and BMI group, we conducted separate analyses in each BMI group. In patients with normal BMI, the 4-year OS was similarly excellent between younger vs older AYAs (83%

Table 1. Patient, disease, and treatment characteristics of patients with ALL treated on DFCI ALL protocols

	All patients N = 388	Normal BMI group, n = 207	Overweight/obese BMI groups, n = 181	P value
Age group (2 groups)				<.001
15-29 y	254 (65)	164 (79)	90 (50)	
30-50 y	134 (35)	43 (21)	91 (50)	
Age group (4 groups)				<.001
15-19 y	138 (36)	100 (48)	38 (21)	
20-29 y	116 (30)	64 (31)	52 (29)	
30-39 y	72 (19)	20 (10)	52 (29)	
40-49 y	62 (16)	23 (11)	39 (22)	
Sex (male)	240 (62)	117 (56)	123 (68)	.021
Immunophenotype*				.75
B-ALL	288 (74)	155 (75)	133 (73)	
T-ALL	100 (26)	52 (25)	48 (27)	
Anterior mediastinal mass	77 (20)	42 (20)	35 (19)	.96
CNS involvement				.70
CNS1	303 (78)	165 (80)	138 (76)	
CNS2	43 (11)	23 (11)	20 (11)	
CNS3	13 (3)	6 (3)	7 (4)	
Traumatic/unknown	29 (8)	13 (6)	16 (9)	
WBC ($\times 10^9/L$, median, IQR)	11.8 (4.1-45.2)	11.95 (4-46.8)	11.55 (4.9-44.4)	.94
Cytogenetics				
Normal	102 (26)	55 (27)	47 (26)	.89
t(9;22)	48 (12)	14 (7)	34 (19)	<.001
Complex	12 (3)	6 (3)	6 (3)	.82
Hyperdiploid	39 (10)	29 (14)	10 (6)	.006
MLL	24 (6)	12 (6)	12 (7)	.73
Other abnormalities	122 (31)	69 (33)	53 (29)	.39
Unknown	51 (13)	27 (13)	24 (13)	.95
Treatment type				.24
On trial	308 (79)	169 (82)	139 (77)	
Per protocol	80 (21)	38 (18)	42 (23)	
Protocols				.12
Older (00-001 & 01-175)	127 (33)	75 (36)	52 (29)	
Newer (05-001 & 06-254)/as per newer protocols	261 (67)	132 (64)	129 (71)	

BMI groups were calculated per CDC guidelines.

CDC, Center for Disease Control; CNS, central nervous system; IQR, interquartile range 25% to 75%; MLL, mixed lineage leukemia.

*One and 3 patients were diagnosed with T-/myeloid and B-/myeloid mixed phenotype acute leukemia, respectively.

[95% CI, 76-88] vs 85% [95% CI, 69-93], $P = .89$). In contrast, in patients who were overweight/obese, the 4-year OS was higher in younger vs older AYAs (73% [95% CI, 62-81] vs 55% [95% CI, 43-65], $P = .023$; [Figure 3A](#)). Older AYAs in the obese BMI category ($n = 39$) had a particularly poor 4-year OS of 47% (95% CI, 28-64) vs 72% (95% CI, 56-83) in younger AYAs in the obese group ($P = .025$).

The 4-year EFS was 70% (95% CI 65-75) and was higher in patients with a normal BMI vs those with an overweight/obese BMI (77% [95% CI, 70-83] vs 63% [95% CI, 55-70], $P = .003$). In patients with a normal BMI, the 4-year EFS was similar between younger vs older AYAs (78% [95% CI, 70-84] vs 74% [95% CI,

57-85], $P = .63$), whereas in patients in the overweight/obese group, the 4-year EFS was numerically higher in younger vs older AYAs, without statistical significance (71% [95% CI, 60-79] vs 55% [95% CI, 43-65], $P = .11$, [Figure 3B](#)). Four-year EFS was very poor among older AYA patients with obese BMI (49%, 95% CI, 29-66).

In a sensitivity analysis excluding 48 AYAs with *BCR::ABL1* translocation (Philadelphia-negative ALL cohort, $n = 340$), higher OS were seen among AYAs with normal vs overweight/obese BMI (4-year OS, 85% [95% CI, 78-89] vs 67% [95% CI, 58-74], $P = .0004$). As was seen in the entire cohort, OS among AYAs with normal BMI was comparable in younger vs older AYA patients




Figure 2. Comparison of grade 3/4 toxicity rates between BMI groups (normal vs overweight/obese). TG, hypertriglyceridemia.

(4-year OS, 84% [95% CI, 77-89] vs 88% [95% CI, 71-95], $P = .43$), whereas younger AYA patients with obese BMI had better OS compared with older AYA patients in the obese category (74% [95% CI, 56-85] vs 48% [95% CI, 37-67], $P = .05$).

The 4-year CIR in the entire cohort was 20.7% (95% CI, 15.9-25.9) and was not statistically different between normal vs overweight/obese BMI groups (18.2% [95% CI, 11.8-25.4] vs 23.4% [95% CI, 16.6-31.0], $P = .18$, [Figure 4A](#)). In the normal BMI group, the 4-year CIR was not different between younger and older AYAs (17.9%, [95% CI, 10.6-26.9] vs 18.8%, [95% CI, 8.0-33.2], $P = .89$, [Figure 4B](#)). Conversely, among patients who were overweight/obese, the 4-year CIR was numerically lower in younger patients (17.1% [95% CI, 9.0-27.5]) vs older patients (30.1% [95% CI, 19.6-41.2], $P = .13$), [Figure 4C](#)).

The 4-year cumulative incidence of NRM was 7.3% [95% CI, 4.6-10.8] and was lower in patients with normal BMI vs those with overweight/obese BMI (2.8% [95% CI, 0.9-6.7] vs 11.7% [95% CI, 6.9-17.8], $P = .006$, [Figure 5A](#)). Within each BMI group, the cumulative incidence of NRM was similar between younger and older AYAs: normal BMI group: 2.1% (95% CI, 0.4-6.7) vs 5.2% (95% CI, 0.9-15.5, $P = .46$, [Figure 5B](#)); overweight/obese BMI group: 10.1% (95% CI, 4.3-18.6) vs 13.4% (95% CI, 6.5-22.9, $P = .46$), respectively ([Figure 5C](#)).

In univariate analyses, patient (age and BMI), disease (white blood cell count [WBC], immunophenotype, and *BCR::ABL1* translocation), treatment (older vs newer protocols; as per protocol vs on protocol, and alloSCT), and toxicity (hyperglycemia and hypertriglyceridemia) covariates were found to be significantly associated with OS. In the multivariable Cox regression analysis, BMI (overweight/obese vs normal), WBC ($\geq 30,000 \times 10^9/L$ vs $< 30,000 \times 10^9/L$) and immunophenotype (B vs T) were significantly associated with worse OS, whereas hypertriglyceridemia was significantly associated with improved OS ([Table 3](#)). Of note, alloSCT and age were significantly associated with worse OS in

the univariate analysis, but not in the multivariable analysis. In addition, there was a trend toward worse OS with grade 3/4 hyperglycemia in the multivariable analysis (hazard ratio [HR], 1.51; 95% CI, 0.99-2.28, $P = .054$).

In a univariable analysis for EFS, BMI (overweight/obese vs normal), WBC ($> 30 \times 10^9/L$ vs $\leq 30 \times 10^9/L$) and immunophenotype (B- vs T-ALL) were associated with worse survival (BMI: HR, 1.94; 95% CI, 1.18-3.17; $P = .008$; WBC: HR, 2.50; 95% CI, 1.53-4.08; $P < .0001$; and immunophenotype: HR, 2.87; 95% CI, 1.46-5.62; $P = .002$; supplemental Table 5). Conversely, treatment on newer protocols (vs older protocols), which primarily used a pegylated asparaginase as opposed to native asparaginase preparation, and grade 3/4 hypertriglyceridemia were associated with better OS (HR, 0.45; 95% CI, 0.27-0.74; $P = .002$ and HR, 0.46; 95% CI, 0.25-0.84; $P = .011$), respectively.

Effect of hypertriglyceridemia and hyperglycemia on survival and relapse

Given the association between grade 3/4 hypertriglyceridemia and hyperglycemia with survival, we performed an exploratory analysis comparing OS, EFS, CIR, and NRM between patients with vs without grade 3/4 hypertriglyceridemia or hyperglycemia.

The 4-year OS and EFS were higher among patients who experienced grade 3/4 hypertriglyceridemia: OS, 88.4% (95% CI, 79.4-93.6) vs 69.6% (95% CI, 63.2-75.0, $P = .0001$, supplemental Figure 1A); EFS, 83.9% (95% CI, 74.2-90.2) vs 64.4% (95% CI, 57.6-70.5), $P = .002$, supplemental Figure 1B). The CIR rates were lower among patients who experienced grade 3/4 hypertriglyceridemia vs those that did not (11.4%, [95% CI, 5.5-19.7] vs 25%, [95% CI, 18.8-31.7], $P = .048$, supplemental Figure 1C). Conversely, the rate of NRM was comparable between patients with vs without grade 3/4 hypertriglyceridemia (5.1%, [95% CI, 1.6-11.7] vs 8.2%, [95% CI, 4.9-12.7], respectively, $P = .39$).

Table 2. Grade 3/4 metabolic toxicities during different phases of treatment

Grade 3/4 toxicity	Induction phase			Consolidation phase			Maintenance/ posttreatment phase			Overall		
	Normal, %	Overweight/obese, %	P value	Normal, %	Overweight/obese, %	P value	Normal, %	Overweight/obese, %	P value	Normal, %	Overweight/obese, %	P value
Elevated AST	6.0	10.4	.14	9.9	19.3	.023	5.5	9.5	.23	14.4	26.6	.005
Elevated ALT	13.7	22.1	.046	29.1	37.9	.12	19.5	24.1	.38	38.9	50.3	.031
Elevated bilirubin	4.2	14.7	.001	3.3	11.4	.011	0	2.6	.11	6.7	23.1	<.0001
Elevated TG	1.2	6.1	.019	27.8	32.1	.42	0	4.3	.023	24.4	29.5	.29
Elevated glucose	18.5	28.8	.026	12.6	20.7	.06	2.3	8.6	.028	24.4	36.4	.014

TG, triglycerides.

*Fisher exact test used.

Conversely, the 4-year OS and EFS were lower among patients who experienced grade 3/4 hyperglycemia vs those who did not: 71.0% (95% CI, 60.8-79.0) vs 76.3% (95% CI, 70.2-81.3, $P = .022$, supplemental Figure 2A); and 62.9% (95% CI, 52.3-71.8) vs 73.6% (95% CI, 67.0-79.1, $P = .006$, supplemental Figure 2B), respectively. The 4-year CIR was 25.5% (95% CI, 16.3-35.8) among patients who experienced grade 3/4 hyperglycemia and 18.5% (95% CI, 13.2-24.5) among patients who did not ($P = .32$). The rate of NRM in patients with vs without grade 3/4 hyperglycemia was 9.5% (95% CI, 4.7-16.5) vs 6.1% (95% CI, 3.2-10.4) respectively, $P = .14$.

Of note, no association was seen between grade 3/4 hypertriglyceridemia and pancreatitis (30% with vs 70% without hypertriglyceridemia, respectively, $P = .6$).

Discussion

In this study we examined the association between BMI, treatment-related toxicity, and survival among AYA patients with ALL treated on, or per, DFCI consortium pediatric protocols. Among 388 AYA patients, being overweight or obese was associated with higher NRM (11.7% vs 2.8%, $P = .006$), worse EFS (4-year EFS, 63% vs 77%, $P = .003$), and worse OS (4-year OS, 64% vs 83%, $P = .0001$).

Given the association between elevated BMI and older age, we conducted separate analyses within each BMI group to understand the contribution of each of these factors to patient outcomes. We found excellent outcomes among AYAs with normal BMI, regardless of age. Younger and older AYAs with normal BMI had 4-year NRM of 2.1% vs 5.2%, $P = .46$; CIR of 17.9% vs 18.8%, $P = .89$; and 4-year OS of 83% vs 85%, $P = .89$. AYAs, particularly older AYAs, with an overweight or obese BMI had inferior outcomes. Among AYAs with an overweight or obese BMI, those in older vs younger AYA groups were more likely to not survive (4-year OS, 55% vs 73%, $P = .023$), which appeared to be principally driven by an increased 4-year CIR (30.1 vs 17.1%, $P = .13$). NRM mortality was similar between younger and older AYAs with an overweight or obese BMI (10% vs 13%, $P = .46$). The lack of statistical difference in CIR between older vs younger AYAs in the overweight/obese group is because of late relapse rates (after 4 years) as seen in Figure 5.

Our finding that elevated BMI adversely affects OS is consistent with analyses of patients enrolled on the Cancer and Leukemia Group B (CALGB) 10403 trial in which higher BMI was also associated with inferior outcomes.¹⁴ We also show that the impact of obesity is most severe in older AYAs. In the CALGB analysis, obesity was associated with disease-free survival on multivariable analysis but it was not significant for OS. In our cohort, obesity was associated with both EFS and OS.

We investigated the association between BMI and age and risk for specific metabolic toxicities, the pattern of those toxicities, and association with survival outcomes. We found that AYA patients with elevated BMI compared with those with normal BMI were more likely to experience metabolic toxicities, including grade 3/4 hepatotoxicity (60.7 vs 42.2%, $P = .0005$) and hyperglycemia (36.4 vs 24.4%, $P = .014$). Conversely, no association was seen between BMI group and rates of grade 3/4 hypertriglyceridemia (29.5% vs 24.4%, $P = .29$). When stratified by age group, higher




Figure 3. Kaplan-Meier survival per BMI and age group. (A) OS; (B) EFS.

rates of grade 3/4 metabolic toxicities were seen only in the younger but not in older AYAs with elevated BMI. This might be related to higher incidence of hyperglycemia and hepatotoxicity

among older patients, irrespective of BMI, because the rate of these abnormalities increase with age, regardless of treatment.^{20,21}




Figure 4. CIR by BMI and age group. (A) All patients by BMI group. (B) Patients with normal BMI by age group. (C) Overweight/obese patients by age group.

The association between BMI and metabolic adverse events has been previously reported in children and AYAs treated for ALL.^{13,22} A recent analysis of 1443 children aged 2 to 18 years treated on the NOPHO ALL2008 protocol demonstrated a higher rate of toxicity overall among children who were obese (defined in the study as a BMI of ≥ 30 kg/m²).²³ A post hoc analysis of the CALGB 10403 and AALL0232 trials showed that elevated BMI was associated with increased grade ≥ 3 adverse events in both cohorts.⁶

Of note, a recent report of younger patients (aged 1-22 years) treated on DFCI consortium protocols did not find association between BMI and several toxicities.²⁴ This difference was likely because of the younger age of the patient cohort and a different approach to classifying toxicities, specifically considering all asparaginase toxicities together instead of analyzing each asparaginase-related toxicity separately.

Regarding the timing of toxicities, the pattern varied: grade 3/4 hepatotoxicity and hypertriglyceridemia were highest during consolidation whereas hyperglycemia was most common during induction. This pattern differs from the post hoc analysis of the CALGB 10403 and AALL0232 trials, which demonstrated that toxicities were most common during induction.⁶ The difference may relate, in part, to the differences between protocols: in CALGB 10403 and AALL0232, asparaginase is given intermittently, whereas DFCI protocols include 30 continuous weeks of asparaginase during the postremission consolidation phase.

Finally, we found an association between several grade 3/4 toxicities and survival. Grade 3/4 hypertriglyceridemia was associated with lower cumulative relapse rates and improved EFS and OS,

including in the multivariable model. In addition, similar to previous studies, no association was seen between grade 3/4 hypertriglyceridemia and pancreatitis.²⁵ Hypertriglyceridemia in our patients is believed to indirectly reflect therapeutic antileukemic asparaginase activity. Further correlative studies with direct measures of asparaginase activity could confirm the utility of triglyceride measurement as an inexpensive and accessible laboratory measurement for clinical asparaginase activity. Interestingly, we have previously shown in our DFCI AYA cohort that osteonecrosis, which is, at least in part, due to asparaginase-associated toxicity, is associated with improved survival.^{5,26} As per worse OS seen in patients with grade 3/4 hyperglycemia, previous studies demonstrated association between hyperglycemia, higher rates of infections, and worse survival in both the pediatric population^{27,28} and in adults treated with hyper-CVAD regimen.²⁹

The mechanism connecting higher BMI with worse survival is largely unknown. Our findings on the association between BMI and higher NRM suggest that a portion of the impact of higher BMI is related to inferior ability to tolerate chemotherapy. This is likely a multifactorial effect, including a possible increased risk for hyperglycemia, infection, and less resilience in the setting of severe complications of treatment, such as sepsis.

Another potential cause for poorer survival could be through disease resistance. Although the association of obesity and relapse in our cohort was of borderline significance, high CIR rates were seen in the older patients in the overweight/obese category, for whom the cumulative risk of relapse reached 30% in 4 years compared with 17% in younger patients in the same BMI category. This association is intriguing given the significant literature suggesting an association between elevated adipose tissue and




Figure 5. Nonrelapse mortality by BMI and age group. (A) All patients by BMI group. (B) Patients with normal BMI by age group. (C) Overweight/obese patients by age group.

Table 3. Univariate and multivariable Cox regression analysis for OS

	Univariate HR (95% CI)	P value	Multivariable HR (95% CI)	P value
Age as continuous variable (y)	1.03 (1.01-1.05)	.003	-	-
Sex (male vs female)	1.06 (.70-1.60)	.79	-	-
BMI (overweight/obese vs normal)	2.26 (1.48-3.45)	<.0001	2.38 (1.56-3.63)	<.0001
WBC (>30 vs ≤30 × 10 ⁹ /L)	1.92 (1.29-2.87)	.001	1.79 (1.20-2.69)	.005
CNS-2 or CNS-3 vs CNS-1	1.55 (0.94-2.55)	.08	-	-
Immunophenotype B- vs T-ALL	2.52 (1.41-4.53)	.002	2.27 (1.26-4.09)	.006
<i>BCR::ABL1</i> translocation (yes vs no)	2.40 (1.46-3.94)	.001	-	-
Complex karyotype (yes vs no)	0.61 (0.15-2.48)	.49	-	-
Hyperdiploid karyotype (yes vs no)	0.81 (.39-1.67)	.57	-	-
MLL rearrangement (yes vs no)	1.58 (0.77-3.27)	.22	-	-
Other karyotype abnormality (yes vs no)	0.81 (0.52-1.26)	.35	-	-
Treatment type (per protocol vs on protocol)	0.49 (0.27-0.91)	.023	-	-
Treatment protocols (newer vs older)	0.60 (0.39-0.92)	.019	-	-
Hepatotoxicity, grade 3/4 (yes vs no)	0.68 (0.45-1.02)	.06	-	-
Hyperglycemia, grade 3/4 (yes vs no)	1.61 (1.07-2.44)	.023	-	-
Hypertriglyceridemia, grade 3/4 (yes vs no)	0.33 (0.18-0.60)	<.0001	0.33 (0.18-0.61)	<.0001
AlloSCT (as time dependent variable)	2.04 (1.26-3.30)	.004	1.31 (.80-2.14)	.28

CNS, central nervous system; MLL, mixed lineage leukemia.

mechanisms that might predict treatment failure. One proposed explanation is that adipose tissue protects lymphoblasts from anthracyclines³⁰ or asparaginase,^{31,32} by providing metabolic “fuel” to leukemia cells or promoting inflammatory response.³³ Another hypothesis is that patients with high BMI receive insufficient exposure to chemotherapy because chemotherapy is administered based on body surface area, which does not increase proportionally to body mass.³⁴ Finally, 2 drugs that form the backbone of ALL regimens, asparaginase and vincristine, are “dose capped,” which may result in more underdosing in patients with elevated BMI.^{35,36}

Because obesity is a serious disease with increasing rates in the last 20 years,^{37,38} the challenge of treating patients with ALL who are overweight or obese will be more common, and the optimal therapy, especially for older patients with obesity, has yet to be defined. Given that AYAs with obesity fare more poorly with asparaginase-based pediatric regimens as compared with AYAs with a normal BMI,¹⁴ alternative approaches including but not limited to alternative asparaginase dose and schedules should be explored. It is not known whether these patients would have improved outcomes with nonasparaginase-based regimens, such as hyper-CVAD (cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride [Adriamycin], and dexamethasone) or approaches currently being evaluated in adults that rely on novel agents.³⁹

In contrast, we found excellent outcomes in older AYA patients with normal BMI, suggesting that fit adults aged ≤50 years with normal BMI might be considered for pediatric regimens in which they may expect to be cured without need for transplantation.^{40,41} Indeed, other groups have demonstrated the ability to apply pediatric regimens to older adults with dose modifications of asparaginase.⁴²

Overall, our findings emphasize that clinicians and clinical investigators should consider both age and BMI in making treatment decisions. This will be best implemented if ongoing and future studies report results based on both age and BMI.

Our study is limited by its retrospective nature and heterogeneous population, which was partially addressed by stratification, and regression and sensitivity analyses. A second limitation is the fact that we conducted our analysis only considering BMI at diagnosis; there may be an additional role for studying weight gain during treatment but such data were not available to us in this cohort. Furthermore, our cohort did not include systematic evaluation of measurable residual disease, which plays a role in decision making throughout the course of treatment in the current era. The association between BMI and persistence of measurable residual disease should be pursued in future studies. Finally, our study has limited data on Hispanic ethnicity, which is associated with both obesity³⁸ and higher rates of ALL.^{43,44} Additional studies evaluating our findings in cohorts with varied ethnic representation are needed. Because prospective clinical trials might not enroll representative populations,⁴⁵ research using registry and retrospective chart review, although imperfect, will also be informative to understand outcomes in populations particularly affected by ALL and obesity, especially the Hispanic community. Efforts to enroll diverse, representative populations in ALL clinical trials should be prioritized.⁴⁶

In conclusion, we show that among AYAs with ALL treated on a pediatric regimen, obesity at diagnosis was associated with increased NRM and inferior EFS and OS. An elevated BMI was associated with particularly high relapse rates and poor survival among AYAs aged >30 years. In contrast, AYAs with normal BMI, regardless of age, had favorable outcomes when treated on this pediatric-inspired regimen. Moreover, we demonstrate, to our knowledge, for the first time, that

hypertriglyceridemia is associated with improved survival and decreased risk of relapse, most likely reflecting asparaginase activity and thus should not be viewed as an adverse event. Future trials of ALL treatments among patients of all ages should study the impact of obesity on treatment toxicity and outcomes.

Acknowledgment

This work was supported by the Foley Family Research Fund.

Authorship

Contribution: S.S., D.J.D., and M.R.L. designed the research; S.S. and Y.K.V. performed data extraction; S.S., Y.F., and D.S.N. analyzed the data; S.S. and M.R.L. wrote the initial draft of the manuscript; Y.F., Y.K.V., A.E.P., L.B.S., L.M.V., A.M.B., S.E.S., R.M.S., M.W., D.S.N., and D.J.D. reviewed the manuscript and contributed to its final version; and all authors reviewed the final version of the manuscript and agreed on submission.

Conflict-of-interest disclosure: L.B.S. reports serving on advisory boards for Jazz, Servier, and Syndax. A.M.B. reports research support from AstraZeneca, Novartis, Roivant, Takeda, Celgene/Bristol Myers Squibb (BMS), GlaxoSmithKline (GSK), and Janssen, and consulting fees from Agios, AbbVie, Acceleron, BMS/

Celgene, Novartis, Gilead, Keros Therapeutics, and Taiho Oncology. S.E.S. reports honoraria from Jazz and Servier. R.M.S. reports consulting fees from AbbVie, AbbVie/Genentech, Actinium, Amgen, Aptevo, Aprea, Arog, AvenCell, BerGenBio, BMS, Boston Pharmaceuticals, Cellularity, CTI Pharma, Epizyme, Foghorn Therapeutics, Gemoab, GSK, Innate, Janssen, Jazz, Kura Oncology, Novartis, Onconova, Rigel, Syntrix, Syros, and Takeda. D.S.N. reports consultancy with The American Society of Hematology Research Collaborative as a senior scientific adviser and reports stock ownership in Madrigal Pharmaceuticals. D.J.D. has served as a consultant for Amgen, Autolys, Agios, Blueprint Pharmaceuticals, Forty-Seven, Gilead, Incyte, Jazz, Novartis, Pfizer, Servier, and Takeda, and received research funding from AbbVie, Glycomimetics, Novartis, and Blueprint Pharmaceuticals. M.R.L. receives research support from AbbVie and Novartis, and has served on advisory boards for Novartis, Jazz, and Pfizer. The remaining authors declare no competing financial interests.

ORCID profiles: S.S., [0000-0001-7245-9652](https://orcid.org/0000-0001-7245-9652); Y.F., [0000-0003-2150-6732](https://orcid.org/0000-0003-2150-6732); A.E.P., [0000-0002-9604-4213](https://orcid.org/0000-0002-9604-4213); D.J.D., [0000-0001-7865-2306](https://orcid.org/0000-0001-7865-2306); M.R.L., [0000-0002-5781-4529](https://orcid.org/0000-0002-5781-4529).

Correspondence: Marlise R. Luskin, Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215; email: marlise_luskin@dfci.harvard.edu.

References

1. Stock W, La M, Sanford B, et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. *Blood*. 2008;112(5):1646-1654.
2. Siegel SE, Stock W, Johnson RH, et al. Pediatric-inspired treatment regimens for adolescents and young adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: a review. *JAMA Oncol*. 2018;4(5):725-734.
3. Grace RF, Dahlberg SE, Neuberg D, et al. The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute Consortium protocols. *Br J Haematol*. 2011;152(4):452-459.
4. Aldoss I, Douer D. How I treat the toxicities of pegasparaginase in adults with acute lymphoblastic leukemia. *Blood*. 2020;135(13):987-995.
5. Valtis YK, Stevenson KE, Place AE, et al. Orthopedic toxicities among adolescents and young adults treated in DFCI ALL Consortium Trials. *Blood Adv*. 2022;6(1):72-81.
6. Advani AS, Larsen E, Laumann K, et al. Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia. *Blood Adv*. 2021;5(2):504-512.
7. Center for Disease Control and Prevention. National Health Statistics Reports. National Health and Nutrition Examination Survey 2017–March 2020 Prevalence Data Files Development of Files and Prevalence Estimates for Selected Health Outcomes. 14 June 2021. Accessed 15 February 2023. <https://stacks.cdc.gov/view/cdc/106273>
8. Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. *Gastroenterology*. 2011;140(1):124-131.
9. Hossain P, Kawan B, El Nahas M. Obesity and diabetes in the developing world – a growing challenge. *N Engl J Med*. 2007;356(3):213-215.
10. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. *Nature*. 2006;444(7121):840-846.
11. Bays HE, Toth PP, Kris-Etherton PM, et al. Obesity, adiposity, and dyslipidemia: a consensus statement from the National Lipid Association. *J Clin Lipidol*. 2013;7(4):304-383.
12. Egnell C, Närhinen H, Merker A, et al. Changes in body mass index during treatment of childhood acute lymphoblastic leukemia with the Nordic ALL2008 protocol. *Eur J Haematol*. 2022;109(6):656-663.
13. Denton CC, Rawlins YA, Oberley MJ, Bhojwani D, Orgel E. Predictors of hepatotoxicity and pancreatitis in children and adolescents with acute lymphoblastic leukemia treated according to contemporary regimens. *Pediatr Blood Cancer*. 2018;65(3):e26891.
14. Stock W, Luger SM, Advani AS, et al. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. *Blood*. 2019;133(14):1548-1559.
15. Butturini AM, Dorey FJ, Lange BJ, et al. Obesity and outcome in pediatric acute lymphoblastic leukemia. *J Clin Oncol*. 2007;25(15):2063-2069.

16. Vrooman LM, Stevenson KE, Supko JG, et al. Postinduction dexamethasone and individualized dosing of *Escherichia Coli* L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study—Dana-Farber Cancer Institut. *J Clin Oncol*. 2013;31(9):1202-1210.
17. Deangelo DJ, Stevenson KE, Dahlberg SE, et al. Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia. *Leukemia*. 2015;29(3):526-534.
18. Place AE, Stevenson KE, Vrooman LM, et al. Intravenous pegylated asparaginase versus intramuscular native *Escherichia coli* L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial. *Lancet Oncol*. 2015;16(16):1677-1690.
19. DeAngelo DJ, Stevenson K, Neuberg DS, et al. A multicenter phase II study using a dose intensified pegylated-asparaginase pediatric regimen in adults with untreated acute lymphoblastic leukemia: a DFCI ALL Consortium Trial. *Blood*. 2015;126(23):80.
20. Kim IH, Kisseleva T, Brenner DA. Aging and liver disease. *Curr Opin Gastroenterol*. 2015;31(3):184-191.
21. Chia CW, Egan JM, Ferrucci L. Age-related changes in glucose metabolism, hyperglycemia, and cardiovascular risk. *Circ Res*. 2018;123(7):886-904.
22. Pui C-H, Burghen GA, Bowman WP, Aur RJA. Risk factors for hyperglycemia in children with leukemia receiving l-asparaginase and prednisone. *J Pediatr*. 1981;99(1):46-50.
23. Egnell C, Heyman M, Jónsson ÓG, et al. Obesity as a predictor of treatment-related toxicity in children with acute lymphoblastic leukaemia. *Br J Haematol*. 2022;196(5):1239-1247.
24. Paolino JD, Flamand Y, Stevenson KE, et al. Impact of age, body surface area, and body mass index on pegaspargase toxicity and pharmacokinetics: a report from the DFCI ALL Consortium. *Blood*. 2021;138(suppl 1):3396.
25. Raja RA, Schmiegelow K, Sørensen DN, Frandsen TL. Asparaginase-associated pancreatitis is not predicted by hypertriglyceridemia or pancreatic enzyme levels in children with acute lymphoblastic leukemia. *Pediatr Blood Cancer*. 2017;64(1):32-38.
26. Valtis YK, Place AE, Silverman LB, Vrooman LM, DeAngelo DJ, Luskin MR. Orthopaedic adverse events among adolescents and adults treated with asparaginase for acute lymphoblastic leukaemia. *Br J Haematol*. 2022;198(3):421-430.
27. Sonabend RY, McKay SV, Okcu MF, Yan J, Haymond MW, Margolin JF. Hyperglycemia during induction therapy is associated with increased infectious complications in childhood acute lymphocytic leukemia. *Pediatr Blood Cancer*. 2008;51(3):387-392.
28. Sonabend RY, McKay SV, Okcu MF, Yan J, Haymond MW, Margolin JF. Hyperglycemia during induction therapy is associated with poorer survival in children with acute lymphocytic leukemia. *J Pediatr*. 2009;155(1):73-78.
29. Weiser MA, Cabanillas ME, Konopleva M, et al. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen. *Cancer*. 2004;100(6):1179-1185.
30. Sheng X, Tucci J, Parmentier J-H, et al. Adipocytes cause leukemia cell resistance to daunorubicin via oxidative stress response. *Oncotarget*. 2016;7(45):73147-73159.
31. Ehsanipour EA, Sheng X, Behan JW, et al. Adipocytes cause leukemia cell resistance to L-asparaginase via release of glutamine. *Cancer Res*. 2013;73(10):2998-3006.
32. Behan JW, Yun JP, Proektor MP, et al. Adipocytes impair leukemia treatment in mice. *Cancer Res*. 2009;69(19):7867-7874.
33. Orgel E, Sea JL, Mittelman SD. Mechanisms by which obesity impacts survival from acute lymphoblastic leukemia. *J Natl Cancer Inst Monogr*. 2019;2019(54):152-156.
34. Hunter RJ, Navo MA, Thaker PH, Bodurka DC, Wolf JK, Smith JA. Dosing chemotherapy in obese patients: actual versus assigned body surface area (BSA). *Cancer Treat Rev*. 2009;35(1):69-78.
35. Hall RG 2nd, Jean GW, Sigler M, Shah S. Dosing considerations for obese patients receiving cancer chemotherapeutic agents. *Ann Pharmacother*. 2013;47(12):1666-1674.
36. Griggs JJ, Mangu PB, Temin S, Lyman GH. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline. *J Oncol Pract*. 2012;8(4):e59-e61.
37. Ng M, Fleming T, Robinson M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet*. 2014;384(9945):766-781.
38. Ogden CL, Carroll MD, Fryar CD, Flegal KM. Prevalence of obesity among adults and youth: United States, 2011-2014. *NCHS Data Brief*. 2015;(219):1-8.
39. Luskin MR. Acute lymphoblastic leukemia in older adults: curtain call for conventional chemotherapy? *Hematology*. 2021;2021(1):7-14.
40. Seftel MD, Neuberg D, Zhang M-J, et al. Pediatric-inspired therapy compared to allografting for Philadelphia chromosome-negative adult ALL in first complete remission. *Am J Hematol*. 2016;91(3):322-329.
41. Wieduwilt MJ, Stock W, Advani A, et al. Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALG. *Leukemia*. 2021;35(7):2076-2085.
42. Patel AA, Heng J, Dworkin E, et al. Efficacy and tolerability of a modified pediatric-inspired intensive regimen for acute lymphoblastic leukemia in older adults. *EJHAEM*. 2021;2(3):413-420.
43. Barrington-Trimis JL, Cockburn M, Metayer C, Gauderman WJ, Wiemels J, McKean-Cowdin R. Rising rates of acute lymphoblastic leukemia in Hispanic children: trends in incidence from 1992 to 2011. *Blood*. 2015;125(19):3033-3034.

44. Pullarkat ST, Danley K, Bernstein L, Brynes RK, Cozen W. High lifetime incidence of adult acute lymphoblastic leukemia among Hispanics in California. *Cancer Epidemiol Biomarkers Prev.* 2009;18(2):611-615.
45. Muffly L, Alvarez E, Lichtensztajn D, Abrahão R, Gomez SL, Keegan T. Patterns of care and outcomes in adolescent and young adult acute lymphoblastic leukemia: a population-based study. *Blood Adv.* 2018;2(8):895-903.
46. Hantel A, Kohlschmidt J, Eisfeld AK, et al. Inequities in Alliance Acute Leukemia Clinical Trial and Biobank Participation: defining targets for intervention. *J Clin Oncol.* 2022;40(32):3709-3718.